During the recent session, Bluebird bio Inc (NASDAQ:BLUE)’s traded shares were 1.02 million, with the beta value of the company hitting 0.77. At the last check today, the stock’s price was $1.20, reflecting an intraday gain of 1.27% or $0.02. The 52-week high for the BLUE share is $5.53, that puts it down -360.83 from that peak though still a striking 26.67% gain since the share price plummeted to a 52-week low of $0.88. The company’s market capitalization is $230.32M, and the average intraday trading volume over the past 10 days was 6.55 million shares, and the average trade volume was 9.46 million shares over the past three months.
Bluebird bio Inc (NASDAQ:BLUE) trade information
Bluebird bio Inc (BLUE) registered a 1.27% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.27% in intraday trading to $1.20, hitting a weekly high. The stock’s 5-day price performance is -12.45%, and it has moved by -14.03% in 30 days. Based on these gigs, the overall price performance for the year is -63.79%. The short interest in Bluebird bio Inc (NASDAQ:BLUE) is 34.04 million shares and it means that shorts have 2.91 day(s) to cover.
Bluebird bio Inc (BLUE) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -273.70% this quarter and then drop -323.80% in the quarter after that. In the rating firms’ projections, revenue will increase 900.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $10.8 million as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $19.55 million by the end of Mar 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $62k and $2.38 million respectively. In this case, analysts expect current quarter sales to grow by 17,319.40% and then jump by 721.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.14%. While earnings are projected to return 10.66% in 2024, the next five years will return 45.80% per annum.
BLUE Dividends
Bluebird bio Inc is due to release its next quarterly earnings between May 07 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
Bluebird bio Inc insiders own 0.38% of total outstanding shares while institutional holders control 70.61%, with the float percentage being 70.88%. State Street Corporation is the largest shareholder of the company, while 253 institutions own stock in it. As of Jun 29, 2023, the company held over 16.36 million shares (or 15.29% of all shares), a total value of $53.82 million in shares.
The next largest institutional holding, with 8.79 million shares, is of Blackrock Inc.’s that is approximately 8.22% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $28.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of Bluebird bio Inc (BLUE) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 13.88 million shares. This amounts to just over 12.98 percent of the company’s overall shares, with a $52.34 million market value. The same data shows that the other fund manager holds slightly less at 3.39 million, or about 3.17% of the stock, which is worth about $11.15 million.
